Clinical Trial to Evaluate a Drug for the Treatment of LHON
The objective of this study is to evaluate the safety, tolerability, and efficacy of a topical ophthalmic solution in the treatment of subjects with Leber’s Hereditary
Optic Neuropathy (LHON). The study drug has been shown to enhance or benefit mitochondria function in studies done on cells grown in the laboratory.
Investigator: Alfredo Sadun, MD, PhD
Clinical Trial to Evaluate the Efficacy of a Single Intravitreal Injection for patients with LHON
The goal of this clinical trial is to assess the effectiveness of a gene therapy, in improving the visual outcome in patients with LHON due to a mitochondrial mutation.
Investigator: Laura Bonelli, MD, Gad Heilweil, MD, Jean-Pierre Hubschman, MD, Alfredo Sadun, MD, PhD, and Irena Tsui, MD
Clinical Trial of an investigational drug for patients with Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
The purpose of this research study is to test whether the experimental drug, QPI-1007, helps prevent loss of visual acuity (sharpness of your vision). QPI-1007 is being developed to treat vision loss that can occur when there is not enough blood flow to the nerve tissue in the eye; that is, after a stroke of the optic nerve or NAION.
Investigator: Peter Quiros, MD